You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ASTX727

Showing 1 - 25 of 35
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Trial in Houston (ASTX727, ASTX029-01)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Houston, Texas
    MD Anderson Cancer Center
Oct 27, 2023

MDS Trial in Hangzhou (IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine)

Recruiting
  • Myelodysplastic Syndromes
  • IV Decitabine
  • +2 more
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,Zhejiang University School of Medi
Oct 23, 2023

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +3 more
  • Biopsy
  • +4 more
  • (no location specified)
Jan 4, 2023

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts Trial (Biospecimen

Not yet recruiting
  • Chronic Myelomonocytic Leukemia
  • +3 more
  • Biospecimen Collection
  • +3 more
  • (no location specified)
Oct 27, 2022

Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Head Neck Cancer Trial in Boston (Oral Decitabine, Durvalumab)

Active, not recruiting
  • Head and Neck Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 30, 2022

Acute Myeloid Leukemia Trial in Houston (SNDX-5613, Venetoclax, ASTX727)

Recruiting
  • Acute Myeloid Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)

Recruiting
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Lower-risk Myelodysplastic Trial in Tokyo (ASTX727)

Active, not recruiting
  • Lower-risk Myelodysplastic
  • ASTX727
  • Tokyo, Japan
    NTT Medical Center Tokyo
Jan 14, 2022

Acute Myeloid Leukemia Trial in Nashville (Biopsy of Bone, Cytarabine, Daunorubicin)

Recruiting
  • Acute Myeloid Leukemia
  • Biospecimen Collection
  • +5 more
  • Buffalo, New York
  • +1 more
Jan 27, 2023

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Portland (Decitabine and

Not yet recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Decitabine and Cedazuridine
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
May 25, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Hodgkin Lymphoma Trial in New York (Decitabine and

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +5 more
  • Decitabine and Cedazuridine
  • Nivolumab
  • New York, New York
    NY011 Laura and Isaac Perlmutter Cancer Center at NYU Langone
Jul 8, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 1, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Decitabine and Cedazuridine
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Apr 19, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Decitabine and Cedazuridine
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Malignant Peripheral Nerve Sheath Tumors (MPNST) Trial in United States (ASTX727)

Recruiting
  • Malignant Peripheral Nerve Sheath Tumors (MPNST)
  • ASTX727
  • Basking Ridge, New Jersey
  • +6 more
Aug 25, 2022

Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8 Trial in Buffalo

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 27, 2022

Acute Myeloid Leukemia Trial in Houston (Decitabine and Cedazuridine, Enasidenib, Gilteritinib)

Recruiting
  • Acute Myeloid Leukemia
  • Decitabine and Cedazuridine
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 10, 2022

MDS, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia Trial in Sydney (Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET,

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
  • Defactinib
  • Sydney, New South Wales, Australia
  • +3 more
Jan 12, 2023

MDS Trial (Decitabine/Cedazuridine, Magrolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • (no location specified)
Apr 18, 2023

Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary

Suspended
  • Locally Advanced Unresectable Primary Central Chondrosarcoma
  • +2 more
  • Phoenix, Arizona
  • +38 more
Feb 2, 2023

Acute Myeloid Leukemia Trial in Canada, Spain, United States (Decitabine and Cedazuridine (ASTX727), Venetoclax)

Recruiting
  • Acute Myeloid Leukemia
  • Los Angeles, California
  • +15 more
Jul 29, 2022

MDS, AML Trial in France (ASTX727, Donor Lymphocyte Infusions)

Recruiting
  • MDS
  • AML
  • ASTX727
  • Donor Lymphocyte Infusions
  • Amiens, France
  • +15 more
Jul 21, 2022

Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor Trial in Indianapolis, Winston-Salem

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Indianapolis, Indiana
  • +1 more
Sep 28, 2021

Acute Myeloid Leukemia Trial in United States (ASTX660, ASTX727)

Active, not recruiting
  • Acute Myeloid Leukemia
  • San Francisco, California
  • +14 more
Jan 24, 2022